Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem
PubMed
21536664
DOI
10.1093/annonc/mdr065
PII: S0923-7534(19)34378-9
Knihovny.cz E-zdroje
- MeSH
- benzensulfonáty aplikace a dávkování MeSH
- dospělí MeSH
- fenylmočovinové sloučeniny MeSH
- indoly aplikace a dávkování MeSH
- inhibitory proteinkinas terapeutické užití MeSH
- karcinom z renálních buněk farmakoterapie sekundární MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory ledvin farmakoterapie sekundární MeSH
- niacinamid analogy a deriváty MeSH
- protokoly antitumorózní kombinované chemoterapie terapeutické užití MeSH
- pyridiny aplikace a dávkování MeSH
- pyrroly aplikace a dávkování MeSH
- registrace * MeSH
- retrospektivní studie MeSH
- rozvrh dávkování léků MeSH
- senioři MeSH
- sorafenib MeSH
- sunitinib MeSH
- tyrosinkinasy antagonisté a inhibitory MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
- Názvy látek
- benzensulfonáty MeSH
- fenylmočovinové sloučeniny MeSH
- indoly MeSH
- inhibitory proteinkinas MeSH
- niacinamid MeSH
- pyridiny MeSH
- pyrroly MeSH
- sorafenib MeSH
- sunitinib MeSH
- tyrosinkinasy MeSH
BACKGROUND: Sequential therapy with tyrosine kinase inhibitors (TKIs), sunitinib and sorafenib, is a common treatment choice for patients with advanced/metastatic renal cell carcinoma (mRCC) despite lack of randomised trials. The aim of this retrospective registry-based study was to analyse the outcomes of RCC patients treated with sunitinib-sorafenib or sorafenib-sunitinib sequence. PATIENTS AND METHODS: The Czech database containing information on patients treated for mRCC using targeted agents was used as a source of data for retrospective analysis. There were 138 patients treated with sunitinib-sorafenib sequence and 122 patients treated with sorafenib-sunitinib sequence. RESULTS: Progression-free survival (PFS) was 17.7 months for patients treated with sunitinib-sorafenib sequence and 18.8 months for those receiving sorafenib followed by sunitinib (P = 0.47). Overall survival (OS) at 1 year was 83% [95% confidence interval (CI) 77% to 90%] for patients treated with sunitinib-sorafenib and 84% (95% CI 77% to 91%) for sorafenib-sunitinib patients (P = 0.99). Treatment toxic effects were predictable but a significant proportion of patients (up to 14%-25% for different lines of therapy and used TKI) switched between TKIs or discontinued TKI therapy because of toxicity. CONCLUSIONS: In contrast to most of the previously published reports, we have not observed improved PFS or OS for mRCC patients treated with the sorafenib-sunitinib sequence as compared to the sunitinib-sorafenib sequence.
Citace poskytuje Crossref.org
Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib
Neopterin as a biomarker of immune response in cancer patients
Risk factors of atherosclerosis during systemic therapy targeting vascular endothelial growth factor
